Shire (NASDAQ:SHPG) had its price objective increased by B. Riley to $200.00 in a research note published on Thursday morning. B. Riley currently has a buy rating on the biopharmaceutical company’s stock.
SHPG has been the topic of a number of other reports. Cowen set a $225.00 target price on Shire and gave the stock a buy rating in a research note on Friday, January 5th. JPMorgan Chase cut Shire from an overweight rating to a neutral rating and lowered their target price for the stock from $200.00 to $150.00 in a research note on Monday, February 19th. Zacks Investment Research upgraded Shire from a sell rating to a hold rating in a research note on Friday, March 23rd. Piper Jaffray reiterated a hold rating on shares of Shire in a research note on Wednesday, January 3rd. Finally, Cantor Fitzgerald set a $222.00 target price on Shire and gave the stock a buy rating in a research note on Wednesday, December 27th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and eleven have given a buy rating to the stock. The stock currently has a consensus rating of Buy and an average price target of $204.64.
NASDAQ:SHPG traded up $0.48 during trading hours on Thursday, hitting $161.22. 1,939,078 shares of the company traded hands, compared to its average volume of 1,455,241. The company has a current ratio of 0.97, a quick ratio of 0.55 and a debt-to-equity ratio of 0.46. Shire has a one year low of $123.73 and a one year high of $192.15. The stock has a market cap of $49,404.84, a PE ratio of 10.79, a price-to-earnings-growth ratio of 1.28 and a beta of 1.31.
Shire (NASDAQ:SHPG) last issued its quarterly earnings data on Thursday, April 26th. The biopharmaceutical company reported $3.37 earnings per share for the quarter, missing the consensus estimate of $3.58 by ($0.21). Shire had a net margin of 28.17% and a return on equity of 14.19%. sell-side analysts forecast that Shire will post 15.22 earnings per share for the current fiscal year.
The business also recently announced a semiannual dividend, which will be paid on Tuesday, April 24th. Shareholders of record on Friday, March 9th will be issued a dividend of $0.8937 per share. This represents a yield of 1.33%. The ex-dividend date is Thursday, March 8th. This is a positive change from Shire’s previous semiannual dividend of $0.15. Shire’s payout ratio is presently 6.93%.
Hedge funds have recently bought and sold shares of the business. SeaCrest Wealth Management LLC purchased a new position in Shire during the 4th quarter valued at about $107,000. Avestar Capital LLC purchased a new position in Shire during the 4th quarter valued at about $116,000. Amica Retiree Medical Trust purchased a new position in Shire during the 4th quarter valued at about $120,000. Steward Partners Investment Advisory LLC purchased a new position in Shire during the 3rd quarter valued at about $159,000. Finally, Benjamin F. Edwards & Company Inc. grew its holdings in Shire by 277.4% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 1,253 shares of the biopharmaceutical company’s stock valued at $194,000 after buying an additional 921 shares in the last quarter. 19.58% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Shire (SHPG) PT Raised to $200.00 at B. Riley” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/20/shire-shpg-pt-raised-to-200-00-at-b-riley.html.
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells specialist medicines for people with rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.